Prelude Therapeutics Inc
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $12.1 | $7.0 | — | — | — |
| Operating income | -$104.6 | -$139.7 | -$132.3 | -$123.5 | -$113.7 |
| Net income | -$99.5 | -$127.2 | -$121.8 | -$115.4 | -$111.7 |
| Cash Flow Statement | |||||
| Free cash flow | -$56.4 | -$103.7 | -$110.6 | -$86.7 | -$85.9 |
Shares outstanding 79.8M · Free float 62.5%
Annual filing data through FY ended December 31, 2025; float as of October 3, 2026.